UBS Group
EBACU

UBS Group’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

UBS Group’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,384
Closed -$14K – 11540
2022
Q3 		$14K Hold
1,384
– – ﹤0.01% 7979
2022
Q2 		$14K Buy
1,384
+100
+8% +$985 ﹤0.01% 7456
2022
Q1 		$13K Buy
1,284
+205
+19% +$2.03K ﹤0.01% 8119
2021
Q4 		$11K Buy
1,079
+200
+23% +$1.98K ﹤0.01% 8721
2021
Q3 		$9K Buy
+879
New +$8.73K ﹤0.01% 8143

Other funds holding EBACU

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
TAM
Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return

UBS Group's EBACU Position: Q4 2022 in Review

UBS Group sold out of European Biotech Acquisition Corp. Units (EBACU) in Q4 2022, closing a stake of 1,384 shares — an estimated $14K sold.

UBS Group first reported a position in EBACU in Q3 2021 and held it in 5 quarters. The position peaked at $14K in Q3 2022. 11 funds tracked by Wall St. Rank hold EBACU as of Q4 2022.

  • UBS Group reported no remaining European Biotech Acquisition Corp. Units position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 1,384 European Biotech Acquisition Corp. Units shares in Q4 2022, an estimated $14K.
  • UBS Group first reported a position in European Biotech Acquisition Corp. Units in Q3 2021 and held it in 5 quarters.
  • UBS Group's European Biotech Acquisition Corp. Units position peaked at $14K in Q3 2022.
  • 11 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.